Connect with us

Hi, what are you looking for?

Economy

Pfizer vaccine only slightly less effective against key South African mutations — study

While these findings don’t indicate the need for a new vaccine to address the emerging variants, Pfizer and BioNTech are prepared to respond if a variant of SARS-CoV-2 shows evidence of escaping immunity by the coronavirus disease 2019 (COVID-19) vaccine, the companies said. Image via REUTERS/Dado Ruvic/Illustration/File Photo

NEW YORK — Pfizer Inc. and BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appeared to lose only a small bit of effectiveness against an engineered virus with three key mutations from the new coronavirus variant found in South Africa, according to a laboratory study conducted by the US drugmaker.

The study by Pfizer and scientists from the University of Texas Medical Branch (UTMB), which has not yet been peer-reviewed, showed a less than two-fold reduction in antibody titer levels, indicating the vaccine would likely be effective in neutralizing a virus with the so-called E484K and N501Y mutations found in the South African variant.

The study was conducted on blood taken from people who had received the vaccine. Its findings are limited because it does not look at the full set of mutations found in the new South African variant.

While these findings don’t indicate the need for a new vaccine to address the emerging variants, Pfizer and BioNTech are prepared to respond if a variant of SARS-CoV-2 shows evidence of escaping immunity by the COVID-19 vaccine, the companies said.

The scientists are currently engineering a virus with the full set of mutations and expect to have results from that in around two weeks, according to Pei-Yong Shi, an author of the study and a professor at UTMB.

The results are more encouraging than another non-peer-reviewed study from scientists at Columbia University earlier on Wednesday, which used a slightly different method and showed antibodies generated by the shots were significantly less effective against the South Africa variant.

One possible reason for the difference could be that the Pfizer findings are based on an engineered coronavirus, and the Columbia study used a pseudovirus based on the vesicular stomatitis virus, a different type of virus, UTMB’s Mr. Shi said. He said he believes that finding in pseudoviruses should be validated using the real virus.

The study also showed even better results against several key mutations from the highly transmissible UK variant of the virus. Mr. Shi said they were also working on an engineered virus with the full set of mutations from that variant as well. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Investing

A rare Mercedes-Benz racing car known as the Mona Lisa of cars has been sold by the company for a record £115 million. The...

Investing

New research has revealed that only one in four civil servants believe their department is following the Government’s National Data Strategy, with skills and...

Economy

Australian mining and logistics firms are interested in doing business in the Philippines according to Australian ambassador Steven J. Robinson, who cited policy reforms...

Investing

As Sunday Times Rich List shows record number of UK billionaires, their gains should be taxed the same as income from work Huge increases...

Investing

A battle is shaping up between major retailers over whether the UK should introduce an online sales tax, with Sainsbury’s demanding it to help...

Investing

The system of executive pay is “broken”, the Church of England’s pension board has said, as it challenged more companies to ease the pain...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.